QuantalX Neuroscience is a medical device company established by neuroscientists who are committed to revolutionizing the current approach of brain health diagnosis. Together with a dedicated team of developers, scientists, physicians, and business leaders we tackle the clinical, economic, and operational challenges leading to late diagnosis and misdiagnosis of neurodegenerative diseases. The Delphi-MD device, powered by our cutting-edge technology, embodies our vision that early diagnosis and access to brain function are crucial in dealing with the significant challenges posed by brain disorders. Our mission is to transform brain health and disease care, steering in a new era of treatment and support.
An Experienced Team
Scientific and Medical Advisors
Want to Impact Brain Health?
Join us: careers@QuantalX.com
Iftach Dolev, PhD
CEO and Founder
Dr. Iftach Dolev is a Neuroscientist and an entrepreneur. Iftach completed his PhD at the Tel-Aviv University in the field of Neuroscience during which he specialized in electrophysiology and non-invasive brain stimulation. His outstanding work granted him with the ‘Royal Society Wolfson’ Research Merit Award for outstanding achievements in the field of Alzheimer’s disease and the ‘Sieratzki’ prize for advances in neuroscience.
During 2014 Iftach founded QuantalX NeuroScience with the vision of bringing neuroscientific world to the clinic, essentially developing the new golden standard tool for early and objective detection of functional brain disorders, by bridging the gap between science advancement and the medical need.
Hila Fogel, PhD
CTO and Founder
Dr. Hilla Fogel is a Neuroscientist and an entrepreneur. Hilla completed her PhD at the Tel-Aviv university in the field of Neuroscience and Computer science. Hilla published a number of pioneering research studies in the leading peer-reviewed journals for which she was granted with the ‘Sieratzki’ prize for advances in neuroscience- best publication award.
During 2014 Hilla founded QuantalX NeuroScience with the vision of bringing neuroscientific world to the clinic, essentially developing the new golden standard tool for early and objective detection of functional brain disorders, by bridging the gap between science advancement and the medical need.
Noa Zifman Mozni
VP Clinical & Regulatory
Noa is a certified CRA, MSc in neurobiology, with vast experience in clinical research management and medical device regulatory requirements.
BA in accounting & economics with distinction (TAU)
MBA with distinction (Open University)
Arviv’s financial experience spends over more than two decades.
Served in various key financial positions, including CFO and deputy-CEO of a hi-tech company.
Some of the duties he successfully carried out during his extended career:
- Business and financial planning
- International tax planning
- Planning and executing complex financial processes
- Managing dozens of employees from various fields
Adi led marketing, sales and biz dev teams for the last 20 years in the healthcare technologies industry, where she launched numerous products successfully at a global scale.
Adi’s expertise lies in differentiating strategic marketing, demand generation, unique sales enablement tools and high- end brand positioning.
Most recently, Adi served as VP marketing at Zebra Medical Vision, VP revenue at MobileODT and Global Marketing Director of Medical Devices at Teva Pharmaceuticals. Adi obtained a B.Sc in Biology from Tel-Aviv University and serves as Recanati School of Management certified director.
Ofri Levy Lamdan
VP Research & Development
Ofri has a solid background in R&D and algorithm development in the medical device industry. She had served as an algorithm engineer in Orsan medical technologies and holds a PhD degree in neuroscience from the Technion, specializing in electrophysiology and signal processing.
Ofri has extensive experience in the neuroscience field, in particular in processing and analysis of multidimensional neural activity signals, as well as in image processing, machine learning, scientific writing and application of research to the clinical field.
Chairman of the Board
Mr. Makov is among Israel’s most respected corporate leaders.
He is the former President & CEO of Teva Pharmaceutical Industries Ltd (2002-2007). Under his leadership Teva became the undisputed global leader in the generic pharmaceutical industry and a global leader in the treatment of Multiple sclerosis. During his tenure the company’s sales increased over four-fold, to approximately $8.5 billion, and its adjusted net income increased approximately six-fold to over $1.8 billion
Prior to joining Teva, Mr. Makov led a number of companies in various industries. Among them was Israel’s first biotech company, Interpharm, which he founded, and later went public in the US. Makov is also the former Chairman of Given Imaging, the developer and world’s leading provider of capsule endoscopy, and Netafim, the pioneer and global leader in smart irrigation solutions.
Today, Mr Israel Makov is Chairman of Sun Pharma, the world’s 4th largest specialty generic pharma company and the largest pharma company in India, Chairman of Nextage Therapeutics, a global pharma company that develop the next generation of cannabinoid based products, and Chairman of QuantalX NeuroScience.
Mr Makov is a member of the Executive Board & Management Committee of the Weizmann Institute of Science, on the Board of Governors of the Technion, President of the Friends of Schneider Children’s Medical Center of Israel and Director at Yeda Research and Development Company Ltd. Mr. Makov is also Chairman of the Gesher Theatre, one of Israel’s leading theaters.
Mr. Makov has a B.Sc. in Agriculture and an M.Sc. in Economics from the Hebrew University in Jerusalem
Kobi Richter, PhD
Dr. Jacob (Kobi) Richter, who co-founded Medinol, is the company’s Chief Technology Officer and leads Medinol’s research & development, manufacturing, quality and regulatory affairs.
Under his leadership, Medinol fundamentally transformed the interventional cardiology industry through innovation and revolutionary technology. With an extremely cost efficient manufacturing operation and best-in-class products, Dr. Richter grew Medinol to become a significant international player in the stenting industry, highly reputable for its commitment to promote scientific advances and health.
Prior to founding Medinol in 1993, Dr. Richter co-founded Orbotech, a leading microelectronic product company listed on NASDAQ. He was the company’s head of product development and later director of marketing and product development. Currently Dr. Richter is a member of Orbotech’s board of directors.
Dr. Richter has also worked as a post-doctoral and research fellow at the Artificial Intelligence Laboratory and Brain Research Department of the Massachusetts Institute of Technology (MIT), and served as head of research and development for the Israeli Air Force.
Dr. Richter has a Ph.D. in Physiology and Pharmacology from Tel Aviv University. He currently serves on the Cardiac Council of Columbia University Medical Center, and on the Advisory Board of the Center for Brains, Minds and Machines (CBMM) in the McGovern Institute for Brain Research, at the Massachusetts Institute of Technology’s Department of Brain and Cognitive Sciences.
Doron is Chairman of the supervisory board of ProDelta Holding B.V., an international private company that consist of a group of companies: ProDelta Investments, ProDelta Management, ProDelta Real Estate, Hovago Cranes and Riwal Holding Group.
Doron has invested as an Angel in few technologic startups as a coach and inspiratory to the team. He is also involved in social initiatives in Brazil, India, Africa and in the Netherlands, and is an active board member of various social organizations.
Doron earned a degree in economics, international commerce and logistics from DAV Bremen in Germany and is a graduate of the senior executive course (O.P.M) at Harvard Business School. In 2016 he was awarded an honorary PHD in philosophy by The university of Haifa.
Ehud Barak, is a former Israeli Prime Minister, Minister of Defense , Minister of Foreign Affairs, Minister of Interior, and Chief of Staff of the Israeli Defense Forces.
Mr. Barak has a B.Sc. in physics and Mathematics from the Hebrew University, Jerusalem and has a M.Sc. in Economic-Engineering Systems from Stanford University, California.
For the last several years, Barak is involved in few Israeli start-ups in various fields: cyber security, public safety, medical devices and medical cannabis.
Active Board Member
Mike Netz is a healthcare executive, former VP at Teva Pharmaceuticals Industries Ltd and GM of Teva-Israel. For the last several years Mike is investing and serves at the board of several Israeli healthcare start-ups as well as BioMed investment committee at Club100Plus Angels.
Mike holds B.A. in Economics & Business Administration and M.B.A. in Marketing & International Management from Tel Aviv University.
Prof. David Tanne, MD
Prof. David Tanne is the president of the Israel Neurological Association. He is a Professor of Neurology at the Technion Institute of Technology and the director of the Stroke and Cognition Institute at the Rambam Health Care Campus. A graduate of the Sackler Faculty of Medicine )Magna cum lauda), He has completed his fellowship in stroke and cerebrovascular diseases during 1996-1998 at the Henry Ford Hospital and Health Sciences Center, Detroit Campus of Case Western University, Detroit, USA.
Prof. Tanne chairs the advisory committee for the Israeli Stroke Register, Israeli Ministry of Health, and is a Member of National Council of Heart and Vascular Disease, the Israeli National Health Councils. Prof. Tanne has published over 250 scientific peer reviewed publications, serves on the editorial board of the journal Stroke and his major areas of interest are stroke, vascular cognitive impairment and brain health.
Nicholas D. Schiff, MD
Medical and Scientific Advisor
Dr. Schiff, is The Jerold B. Katz Professor of Neurology and Neuroscience in the Feil Family Brain and Mind Research Institute at Weill Cornell Medical College, where he also serves as Professor of Neuroscience (with Tenure), Professor of Neurology, and Professor of Public Health. In addition, he is an Attending Neurologist at the New York-Presbyterian-Weill Cornell Medical Center, a Senior Attending Physician at The Rockefeller University Hospital, a member of the Adjunct Faculty of Rockefeller University, and a member of the Program in Neuroscience at the Joan and Sanford I. Weill Graduate School of Sciences. Dr. Schiff is a physician-scientist trained in quantitative systems neuroscience with broad interests in the area of neurological disorders of consciousness.
Jeffrey L. Saver, MD
Medical and Scientific Advisor
Jeffrey Saver is Professor of Neurology at UCLA. Dr. Saver is a Fellow of the Stroke Council of the American Heart Association, a Fellow of the American Academy of Neurology, a member of the American Neurological Association, and a professional member of the National Stroke Association.
Dr. Saver has published more than 200 original research and review articles, more than 30 book chapters, and two edited volumes. His research focuses on stroke prevention, acute stroke treatment, stroke diagnosis, and cognitive and behavioral consequences of stroke. Dr. Saver’s work has been supported by grants from the National Institutes of Health, the American Heart Association, and the National Stroke Association.
Philip B. Gorelick, MD, MPH
Medical and Scientific Advisor
Dr. Philip B. Gorelick is the Medical Director of the Hauenstein Neuroscience Center, Saint Mary’s Health Care, Grand Rapids, MI (February 6, 2012-present), Professor, Translational Neuroscience, Michigan State University College of Human Medicine, and previously was the John S. Garvin Professor and Head, Department of Neurology and Rehabilitation, University of Illinois College of Medicine at Chicago (2003-Jan. 2012) and Jannotta Presidential Professor in the Department or Neurosciences, Rush University.
Dr. Gorelick has numerous publications in the areas of stroke prevention and risk factor identification, vascular dementia, and stroke in African Americans. He received continuous funding from the US National Institute of Health (NIH) from1987-2005 and led two important NIH initiatives.
Col. Dallas C. Hack, MD
Medical and Scientific Advisor
Past director of the Combat Casualty Care Research Program and the Chair, Joint Program Committee 6 (Combat Casualty Care), U.S. Army Medical Research and Materiel Command, Fort Detrick, MD, where he coordinates leading edge research focused on new techniques and products to save the lives and reduce morbidity of troops injured in the line of duty. In addition, he serves as the Chair of Joint Technology Coordinating Group 6 of the Armed Services Biomedical Research Evaluation and Management (ASBREM) Committee. Advances in Combat Casualty Care have reduced battlefield deaths from wounds to historic lows and are improving care at civilian trauma centers.
Col. Hack has been awarded the Bronze Star Medal, Meritorious Service Medal with six Oak Leaf Clusters, the Army Commendation Medal with three Oak Leaf Clusters, and the Army Achievement Medal. He is also the recipient of the Order of Military Medical Merit.
Col. Hack graduated from Loma Linda University School of Medicine in 1976. After a rotating internship in Anesthesiology and a fellowship in Cardiology and Biomathematics, he worked in General Practice and Biomedical Engineering for 9 years, serving as Vice President of Engineering for a number of biomedical companies. He entered active duty in September 1987, to accept a position in clinical research at the US Army Medical Research Institute of Infectious Diseases (USAMRIID) and completed a residency in General Preventive Medicine in 1993. He also has a MPH from Johns Hopkins University, a MSS from the U.S. Army War College, and a CPE from the Certifying Commission in Medical Management.
Mark Hallet, MD
Medical and Scientific Advisor
Dr. Hallett is a National Institutes of Health (NIH) Distinguished Investigator Emeritus after leading the National Institute of Neurological Disorders and Stroke (NINDS) Human Motor Control Section from 1984 to 2022. He is currently the immediate Past-President of the Functional Neurological Disorder Society.
Dr. Hallett is also a past President of the International Parkinson and Movement Disorder Society, a past President of the International Federation of Clinical Neurophysiology, and past Editor-in-Chief of Clinical Neurophysiology.
He has won multiple awards including the World Federation of Neurology Medal for Contributions to Neuroscience and the International Brain Stimulation Award from the Brain Stimulation journal in 2019. His work focuses mainly on principles of motor control and the pathophysiology of movement disorders.
Richard E. Kuntz, MD
Medical and Scientific Advisor
Dr. Kuntz served as the Chief Medical and Scientific Officer for Medtronic plc, as well as President of Medtronic’s Neuromodulation business. Dr. Kuntz is also a cardiologist at the Brigham and Women’s Hospital and Founder of the Harvard Clinical Research Institute at Harvard Medical School in Boston.